939 results on '"Musolino, Caterina"'
Search Results
2. A multivariate analysis of Multiple Myeloma subtype plasma cells
3. SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma
4. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
5. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
6. FITC-Labelled Clone from Phage Display for Direct Detection of Leukemia Cells in Blood
7. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
8. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
9. Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19
10. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
11. Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies
12. Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies
13. The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention
14. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways
15. Raman spectroscopy differentiates between sensitive and resistant multiple myeloma cell lines
16. P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
17. Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib
18. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma
19. Telomerase and telomere biology in hematological diseases: A new therapeutic target
20. Relationship between mitofusin 2 and cancer
21. Mitochondria-Targeted Antioxidant SkQ1 for Gammopathy-Related Corneal Damage
22. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
23. Supplementary Figure 4 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
24. Supplementary Table 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
25. Supplementary Figure 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
26. Supplementary Figure 2 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features
27. Supplementary Figure 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features
28. Supplementary Tables 1 - 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features
29. Supplementary Figure 5 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
30. Supplementary Figure 1 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features
31. Supplementary Figure 1 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
32. Supplementary Figure 5 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features
33. Supplementary Figure 3 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
34. Supplementary Figure 4 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features
35. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells
36. The metabolomic signature of hematologic malignancies
37. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
38. Vaccination of multiple myeloma: Current strategies and future prospects
39. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients
40. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment
41. Challenge test to bisphosphonates in patients with hypersensitivity reactions to drugs
42. Osteonecrosis
43. Use of Bisphosphonates in Hematology
44. Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
45. New Insights into Cold Shock Proteins Effects in Human Cancer: Correlation with Susceptibility, Prognosis and Therapeutical Perspectives
46. Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
47. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
48. New orally active proteasome inhibitors in multiple myeloma
49. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma
50. MicroRNA Profiling in Asthma: Potential Biomarkers and Therapeutic Targets
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.